170 related articles for article (PubMed ID: 28104820)
21. Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer.
Liang T; Tong W; Ma S; Chang P
Oncoimmunology; 2020 Jun; 9(1):1773205. PubMed ID: 32934878
[TBL] [Abstract][Full Text] [Related]
22. Frequency of immunohistochemical loss of mismatch repair protein in double primary cancers of the colorectum and stomach in Japan.
Hayashi T; Arai M; Ueno M; Kinoshita H; Tada Y; Koizumi K; Miki Y; Yamaguchi T; Kato Y; Utsunomiya J; Muto T; Sugihara K
Dis Colon Rectum; 2006 Oct; 49(10 Suppl):S23-9. PubMed ID: 17106811
[TBL] [Abstract][Full Text] [Related]
23. Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma.
Kubecek O; Trojanova P; Molnarova V; Kopecky J
Med Hypotheses; 2016 Aug; 93():74-6. PubMed ID: 27372860
[TBL] [Abstract][Full Text] [Related]
24. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion.
Albacker LA; Wu J; Smith P; Warmuth M; Stephens PJ; Zhu P; Yu L; Chmielecki J
PLoS One; 2017; 12(11):e0176181. PubMed ID: 29121062
[TBL] [Abstract][Full Text] [Related]
25. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer.
Tsang ES; Walker EJ; Carnevale J; Fisher GA; Ko AH
Immunotherapy; 2021 Oct; 13(15):1249-1254. PubMed ID: 34338034
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
Link JT; Overman MJ
Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
[TBL] [Abstract][Full Text] [Related]
27. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
28. Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
Taha T; Reiss A; Amit A; Perets R
BioDrugs; 2020 Dec; 34(6):749-762. PubMed ID: 33141420
[TBL] [Abstract][Full Text] [Related]
29. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
Bae JM; Cho NY; Kim TY; Kang GH
Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in endometrial cancer.
Mahdi H; Chelariu-Raicu A; Slomovitz BM
Int J Gynecol Cancer; 2023 Mar; 33(3):351-357. PubMed ID: 36878570
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
Lupinacci RM; Bachet JB; André T; Duval A; Svrcek M
Surg Oncol; 2019 Mar; 28():121-127. PubMed ID: 30851885
[TBL] [Abstract][Full Text] [Related]
33. [Clinical and molecular consequences of microsatellite instability in human cancers].
Hamelin R; Chalastanis A; Colas C; El Bchiri J; Mercier D; Schreurs AS; Simon V; Svrcek M; Zaanan A; Borie C; Buhard O; Capel E; Zouali H; Praz F; Muleris M; Fléjou JF; Duval A
Bull Cancer; 2008 Jan; 95(1):121-32. PubMed ID: 18230578
[TBL] [Abstract][Full Text] [Related]
34. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of PD-1 blockade in tumors with MMR deficiency.
Lee V; Le DT
Immunotherapy; 2016; 8(1):1-3. PubMed ID: 26643016
[No Abstract] [Full Text] [Related]
36. [Genome-Based Biomarkers of Immune Checkpoint Blockade Therapy].
Adachi K; Tamada K
Gan To Kagaku Ryoho; 2016 Feb; 43(2):143-50. PubMed ID: 27067677
[TBL] [Abstract][Full Text] [Related]
37. Mismatch repair deficiency testing in clinical practice.
Buza N; Ziai J; Hui P
Expert Rev Mol Diagn; 2016; 16(5):591-604. PubMed ID: 26895074
[TBL] [Abstract][Full Text] [Related]
38. Dostarlimab for the treatment of advanced endometrial cancer.
Redondo A; Gallego A; Mendiola M
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):1-9. PubMed ID: 35184615
[TBL] [Abstract][Full Text] [Related]
39. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance.
Scarpa M; Ruffolo C; Canal F; Scarpa M; Basato S; Erroi F; Fiorot A; Dall'Agnese L; Pozza A; Porzionato A; Castagliuolo I; Dei Tos AP; Bassi N; Castoro C
Oncotarget; 2015 Dec; 6(41):43472-82. PubMed ID: 26496037
[TBL] [Abstract][Full Text] [Related]
40. New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.
Cohen R; Svrcek M; Dreyer C; Cervera P; Duval A; Pocard M; Fléjou JF; de Gramont A; André T
Curr Oncol Rep; 2016 Mar; 18(3):18. PubMed ID: 26861657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
